In malignant melanoma (MM), this mutation (and to a smaller extent the less frequent V600K mutation) indicates utility of BRAF inhibitors (such as vemurafenib and dabrafenib) [1, 2], whereas in colorectal cancer (CRC), V600E is suspected to account for resistance to EGFR antibodies in patients harbouring KRAS wild-type tumours [3, 4] as well as indicating a dismal prognosis [5]. This evidence concerns the gene BRAF and Miyoshi myopathy.